Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Propels Lung Leadership Plans, Reimagines Operating Models

Executive Summary

Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.

You may also be interested in...



Gilead Licensing Deal Expands Remdesivir Access, Capacity

Gilead’s voluntary licensing of remdesivir to five companies while temporarily charging no royalty and allowing them pricing latitude for 127 developing countries not only expands market access but tilts the pricing debate in Gilead’s favor. It also brings significant potential add-on manufacturing capacity.

COVID-19 Disruptions Could Lead To Sharp Slowdown In India Pharma Market

An early assessment of the impact of COVID-19 on the Indian pharmaceutical market by IQVIA suggests a significant tapering of growth in 2020, along the lines of similar expectations in some other Asian nations. Some industry experts are endorsing the strained outlook, at least for now.

Was Coronavirus A Factor In Cipla's Albuterol FDA Approval?

The agency said Cipla’s ANDA met all the requirements for approval, but also that there is increased demand for the products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131131

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel